50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis
Recommended Citation
Stein-Gold L, Schuttelaar ML, Prajapati VH, Homey B, Strowd L, Dossenbach M, Liu C, Zhong J, Pierce E, Agell H, Silvestre JF. 50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2024; 91(3):AB58.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Lebrikizumab (LEB) demonstrated superiority vs. placebo in patients with moderate-to-severe atopic dermatitis (AD) at weeks 4 and 16 of ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). At week 16, patients meeting the protocol-defined response were rerandomized 2:2:1 to receive LEB every 2 weeks (LEBQ2W), LEB every 4 weeks (LEBQ4W), or placebo. In week 16 responders continuing treatment with LEB, approximately 80% maintained a 75% improvement in the Eczema Area and Severity Index (EASI 75) and 84% maintained ≥4-point improvement in the Pruritus Numeric Rating Scale (NRS) at week 52. This Kaplan-Meier curve analysis demonstrates the continuous maintenance of a composite endpoint (defined as maintaining either an absolute EASI score of ≤7 or a Pruritus NRS score of ≤4) for 36 weeks following dose switch from LEBQ2W to LEBQ4W. Patients maintaining the composite endpoint and entering the long-term extension study without an event were censored when the last patient completed the maintenance period or at the date of their last visit. Patients receiving systemic rescue before losing the composite endpoint were censored at the date of rescue. At week 16, 98% (116/118) of LEB responders rerandomized to LEBQ4W had met the composite endpoint. Demographics and baseline disease characteristics were similar to the overall study population. At week 52, 91% of patients treated with LEBQ4W continued to maintain either EASI≤7 or Pruritus NRS≤4. Patients with moderate-to-severe AD who switch to LEBQ4W after successful induction treatment with LEBQ2W continue to maintain a high level of skin and itch response at week 52.
Volume
91
Issue
3
First Page
AB58
